PTPRC and leukemia: Mice treated with Apatinib showed a remarkable reduction in leukemia burden, manifested by a significant decrease in the numbers of human CD45+ cells in the peripheral blood, spleen and bone marrow as compared to control mice (Fig. 6a–c).